Overcoming hurdles in developing successful drugs targeting chemokine receptors

Nature Reviews Immunology

Volumn 11, Issue 5, 2011, Pages 355-363

  Schall, Thomas J ^a   Proudfoot, Amanda E I ^a  

^a ChemoCentryx Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 ANHYDRO 2,3 DIDEOXY 3 [[3 [[7,8 DIHYDRO 3 (TRIFLUOROMETHYL) 1,6 NAPHTHYRIDIN 6(5H) YL]CARBONYL] 3 ISOPROPYLCYCLOPENTYL]AMINO] 4 O METHYLPENTITOL; ABN 912; CCX 282 B; CCX 354; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR5; CP 481715; MLN 1202; MLN 3897; MONOCLONAL ANTIBODY; PLACEBO; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CROHN DISEASE; DRUG POTENCY; DRUG TARGETING; ENTERITIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CHEMOKINES; DRUG DISCOVERY; HIV INFECTIONS; HUMANS; INFLAMMATION; MICE; MOLECULAR TARGETED THERAPY; RECEPTORS, CCR1; RECEPTORS, CHEMOKINE;

EID: 79955476625     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2972     Document Type: Review

References (58)

1. Murphy, P.-M. et-al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52, 145-176 (2000).
2. Zlotnik, A., Yoshie, O. & Nomiyama, H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol. 7, 243 (2006).
3. Sallusto, F. & Baggiolini, M. Chemokines and leukocyte traffic. Nature Immunol. 9, 949-952 (2008).
4. Gerard, C. & Rollins, B.-J. Chemokines and disease. Nature Immunol. 2, 108-115 (2001). (Pubitemid 33707927)
5. Viola, A. & Luster, A.-D. Chemokines and their receptors: drug targets in immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 48, 171-197 (2008). (Pubitemid 351756361)
6. Mackay, C.-R. Moving targets: cell migration inhibitors as new anti-inflammatory therapies. Nature Immunol. 9, 988-998 (2008).
7. Charo, I.-F. & Ransohoff, R.-M. The many roles of chemokines and chemokine receptors in inflammation. N.-Engl. J.-Med. 354, 610-621 (2006).
8. Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539-545 (2001). (Pubitemid 32173595)
9. Gulik, R.-M. et-al. Maraviroc for previously treated patients with R5 HIV-1 infection. N.-Engl. J.-Med. 359, 1429-1441 (2006).
10. DiPersio, J.-F., Uy, G.-L., Yasothan, U. & Kirkpatrick, P. Plerixafor. Nature Rev. Drug Disc. 8, 105-107 (2009).
11. Skov, L. et-al. IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. J.-Immunol. 181, 669-679 (2008).
12. Hutchings, C.-J., Koglin, M. & Marshall, F.-H. Therapeutic antibodies directed at G protein-coupled receptors. MAbs 2, 594-606 (2010).
13. Lukacs, N.-W., Oliveira, S.-H. & Hogaboam, C.-M. Chemokines and asthma: redundancy of function or a coordinated effort? J.-Clin. Invest. 104, 995-999 (1999).
14. Power, C.-A. Knock out models to dissect chemokine receptor function in-vivo. J.-Immunol. Methods 273, 73-82 (2003).
15. Geissmann, F., Jung, S. & Littman, D.-R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19, 71-82 (2003). (Pubitemid 36859902)
16. Tacke, F. & Randolph, G.-J. Migratory fate and differentiation of blood monocyte subsets. Immunobiology 211, 609-618 (2006).
17. Bardi, G., Lipp, M., Baggiolini, M. & Loetscher, P. The T-cell chemokine receptor CCR7 is internalized on stimulation with ELC, but not with SLC. Eur. J.-Immunol. 31, 3291-3297 (2001). (Pubitemid 33100521)
18. Mack, M. et-al. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J.-Exp. Med. 187, 1215-1224 (1998).
19. Zimmermann, N., Conkright, J.-J. & Rothenberg, M.-E. CC chemokine receptor-3 undergoes prolonged ligand-induced internalization. J.-Biol. Chem. 274, 12611-12618 (1999).
20. Elsner, J. et-al. Aminooxypentane-RANTES induces CCR3 activation and internalization of CCR3 from the surface of human eosinophils. Int. Arch. Allergy Immunol. 124, 227-229 (2001). (Pubitemid 32304812)
21. Richardson, R.-M., Marjoram, R.-J., Barak, L.-S. & Snyderman, R. Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J.-Immunol. 170, 2904-2911 (2003). (Pubitemid 36302161)
22. Hieshima, K. et-al. CCL28 has dual roles in mucosal immunity as a chemokine with broad-spectrum antimicrobial activity. J.-Immunol. 170, 1452-1461 (2003). (Pubitemid 36139514)
23. Werner, T., Fessele, S., Maier, H. & Nelson, P.-J. Computer modeling of promoter organization as a tool to study transcriptional coregulation. FASEB J. 17, 1228-1237 (2003). (Pubitemid 36775769)
24. Watarai, Y. et-al. Intraallograft chemokine RNA and protein during rejection of MHC-matched/multiple minor histocompatibility-disparate skin grafts. J.-Immunol. 164, 6027-6033 (2000). (Pubitemid 30389852)
25. Lu, B. et-al. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J.-Exp. Med. 187, 601-608 (1998). (Pubitemid 28093362)
26. Peters, W. et-al. Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 98, 7958-7963 (2001). (Pubitemid 32642669)
27. Tsou, C.-L. et-al. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J.-Clin. Invest. 117, 902-909 (2007). (Pubitemid 46556746)
28. Koenecke, C. & Forster, R. CCR9 and inflammatory bowel disease. Expert Opin. Ther. Targets 13, 297-306 (2009).
29. Heydtmann, M. & Adams, D.-H. Understanding selective trafficking of lymphocyte subsets. Gut 50, 150-152 (2002). (Pubitemid 34087923)
30. Kakinuma, T. et-al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J.-Allergy Clin. Immunol. 107, 535-541 (2001). (Pubitemid 32210037)
31. Zheng, X. et-al. Demonstration of TARC and CCR4 mRNA expression and distribution using in-situ RT-PCR in the lesional skin of atopic dermatitis. J.-Dermatol. 30, 26-32 (2003). (Pubitemid 36240954)
32. Cyster, J.-G. Chemokines and cell migration in secondary lymphoid organs. Science 286, 2098-2102 (1999).
33. Moatti, D. et-al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 97, 1925-1928 (2001). (Pubitemid 32239068)
34. Stahl, E.-A. et-al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nature Genet. 42, 508-514 (2010).
35. Quinones, M.-P. et-al. Experimental arthritis in CC-chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. J.-Clin. Invest. 113, 856-866 (2004).
36. Bruhl, H. et-al. Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T-cells. J.-Immunol. 172, 890-898 (2004). (Pubitemid 38113746)
37. Dairaghi, D. et-al. Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354-C in healthy human subjects. Implications for phase-2 dose selection. Clin. Pharmacol. Ther. 30 March 2011 (doi:10.1038/clpt. 2011.33).
38. Berahovich, R.-D. et-al. Proteolytic activation of alternative CCR1 ligands in inflammation. J.-Immunol. 174, 7341-7351 (2005).
39. Haringman, J.-J. et-al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. 54, 2387-2392 (2006).
40. Vergunst, C.-E. et-al. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 58, 1931-1939 (2008).
41. Struthers, M. & Pasternak, A. CCR2 antagonists. Curr. Top. Med. Chem. 10, 1278-1298 (2010).
42. Doodes, P.-D. et-al. CCR5 is involved in resolution of inflammation in proteoglycan-induced arthritis. Arthritis Rheum. 60, 2945-2953 (2009).
43. Van Kuijk, A.-W. et-al. CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial. Ann. Rheum. Dis. 69, 2013-2016 (2010).
44. Gerlag, D.-M. et-al. Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in-patients with rheumatoid arthritis receiving methotrexate. Arthritis Rheum. 62, 3154-3160 (2010).
45. Neote, K., DiGregorio, D., Mak, J.-Y., Horuk, R. & Schall, T.-J. Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell 72, 415-425 (1993). (Pubitemid 23059411)
46. Gao, J.-L. et-al. Structure and functional expression of the human macrophage inflammatory protein 1α/RANTES receptor. J.-Exp. Med. 177, 1421-1427 (1993). (Pubitemid 23117132)
47. Haringman, J.-J., Smeets, T.-J., Reinders-Blankert, P. & Tak, P.-P. Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Ann. Rheum. Dis. 65, 294-300 (2006). (Pubitemid 43268215)
48. Haringman, J.-J., Kraan, M.-C., Smeets, T.-J., Zwinderman, K.-H. & Tak, P.-P. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann. Rheum. Dis. 62, 715-721 (2003).
49. Kraan, M.-C. et-al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum. 43, 1820-1830 (2000).
50. Gladue, R.-P., Brown, M.-F. & Zwillich, S.-H. CCR1 antagonists: what have we learned from clinical trials. Curr. Top. Med. Chem. 10, 1268-1277 (2010).
51. Vergunst, C.-E. et-al. MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase-IIa, double-blind, placebo-controlled, randomized, proof-of-concept study. Arthritis Rheum. 60, 3572-3581 (2009).
52. Proudfoot, A.-E., Power, C.-A. & Schwarz, M.-K. Anti-chemokine small molecule drugs: a promising future? Expert Opin. Investig. Drugs 19, 345-355 (2010).
53. Trebst, C. et-al. CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am. J.-Pathol. 159, 1701-1710 (2001). (Pubitemid 33062513)
54. Balashov, K.-E., Rottman, J.-B., Weiner, H.-L. & Hancock, W.-W. CCR5+ and CXCR3+ T-cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions. Proc. Natl Acad. Sci. USA 96, 6873-6878 (1999).
55. Keshav, S., Johnson, D., Bekker, P. & Schall, T.-J. PROTECT-1 study demonstrated efficacy of the intestine-specific chemokine receptor antagonist CCX282-B (Traficet-EN) in treatment of patients with moderate-to-severe Crohn's disease. Gastroenterology 136, A65 (2009).
56. Keshav, S. et-al. PROTECT-1 study of intestine-specific chemokine receptor antagonist CCX282-B (TRAFICET-EN) in Crohn's disease. Gut 58, A468 (2009).
57. Walters, M. et-al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for the treatment of inflammatory bowel disease. J.-Pharmacol. Exp. Ther. 335, 61-69 (2010).
58. Kenakin, T., Jenkinson, S. & Watson, C. Determining the potency and molecular mechanism of action of insurmountable antagonists. J.-Pharmacol. Exp. Ther. 319, 710-723 (2006).